The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR‐TKI b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Asia Pac J Clin Oncol
Main Authors: Sakata, Yoshihiko, Kawamura, Kodai, Shingu, Naoki, Hiroshige, Shigeo, Yasuda, Yuko, Eguchi, Yoshitomo, Anan, Keisuke, Hisanaga, Junpei, Nitawaki, Tatsuya, Nakano, Aiko, Ichikado, Kazuya
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379949/
https://ncbi.nlm.nih.gov/pubmed/30506897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados